Integrated program takes aim at co-morbidity

Some predicted that drugmakers might boost launch prices to make up for Medicare drug negotiations shrinking profits. Harvard researchers find no evidence of that happening so far.

State PBM reform accelerates through 2026, with Theresa Carnegie of Mintz unpacking new laws, rebate pass-through, spread pricing bans, and compliance risks.

Only 19.1% of commercially insured patients with first-episode psychosis were adherent to antipsychotics in the year after starting treatment.

Prioritizing referral completion as much as referral generation will equip organizations to measure results and improve health outcomes.

Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.

In this discussion, Chad Hatfield, Pharm.D., M.H.A., BCPS, shares his perspective on the evolving role of pharmacy services and the value of collaboration across health care.

CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.

Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.